

Summary

Introduction: The S100B protein is a small dimeric protein which belongs to a group of calcium binding proteins. It is found in astroglial cells in the central nervous system (CNS). The S100B protein is detected, at very low concentrations, in fat tissue, muscle and bone marrow. We can measure this marker in the cerebrospinal fluid, in serum and in urine. The commercially available assay measures the sum of two different dimers (the S100A1B and S100BB) which collectively are called the S100B protein. The level of this marker increases significantly in patients with CNS damage. Studies of patients with isolated head trauma have demonstrated a correlation between serum marker level, neurological findings and outcome. In patients with polytrauma there is a problem to evaluating the initial S100B protein level with regards to CNS damage, because the S100B protein level can be affected by extracerebral sources of the S100B protein.

Aim of study: The aim of our study was to evaluate the significance of the S100B protein in patients with either isolated head trauma or polytrauma and to evaluate the significance of the initial level and the significance of dynamic monitoring of the S100B protein levels. The importance of these levels for predicting primary CNS damage, and for making a prognosis of such patients was also evaluated. Next aim was to evaluate whether there really are extracerebral sources of the S100B protein in patients with polytrauma, and if these sources are eliminated over time. We wanted to select a right interval of the S100B protein sampling.

Patients and Methods: 50 healthy volunteers and 232 patients were included into this study. There were 128 patients with an isolated head injury and 104 patients with polytrauma. The time period from injury to admission was shorter than 6 hours. All patients had an initial CT scan of the head. To evaluate patients we used scoring protocols: GCS, APACHE II, TRISS, GOS, KPS. Like a favourable outcome we rated GOS 4-5 or KPS 80-100, like an unfavourable outcome we rated patients with GOS 1-3 or KPS 0-70. The S100B protein level was done by LIA Essay on a fully automated immunoanalyser Liaison, Dia Sorin, Sweden. The normal level of the S100B protein was established by examination of 50 healthy volunteers and was found to be 0,2 mikrog/L. The S100B protein levels were assessed on admission, and then after 6, 12, 24 and 72 hours. Statistical analysis was performed with SPSS using ANOVA. Data analysis was tested to evaluate the differences among the groups by use Spearman Correlation Coefficients, Odds Ratio and Chi-square test. The statistical significance was determined at the level of $p < 0,05$.

Results: We demonstrated that the initial level of the S100B protein correlates very well with the scoring systems, it means with the severity of a CNS damage, but it poorly correlates with CT scan findings in patients with an isolated head injury patients. The S100B protein levels at 24 and 72 hours correlate significantly with outcome. We demonstrated that the initial S100B protein levels in patients with polytrauma are affected by extracerebral sources of the S100B protein and they have a poor correlation with a CNS damage. The elimination of the extracerebral sources occurs from 24 to 72 hours. S100B protein level in 72 hours correlate with outcome. Dynamic monitoring is very important, because it improves the prognostic potential of the S100B protein. Early normalization of the levels is crucial for prognosis of patients.

Conclusion: This study demonstrated the importance of the dynamic monitoring of the S100B protein levels in patients with a head trauma. It is especially important in patients with a head trauma and other injuries. The initial level correlates with outcome poorly than the next levels in 24 and 72 hours. The evaluation of the dynamic evolution of this marker can help us in estimation of prognosis and can help us in decision about decision on the degree of care. This study could improve our information on the patients with not estimable patient's clinical condition due to the pharmacological sedation.